Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27704705 | 0.86 | FFAR1 (0.58) | FFAR1NR4A2MAOBRAB9AGAA | |
| SCHEMBL23641504 | 0.83 | CYP17A1 (0.51) | FFAR1PPARGPPARACYP1A2CYP2C19 | |
| SCHEMBL14082930 | 0.83 | RAB9A (0.69) | FFAR1LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL19243142 | 0.81 | FFAR1 (0.51) | FFAR1PPARGPPARALTA4HBCHE | |
| SCHEMBL197017 | 0.80 | LMNA (0.72) | FFAR1NR4A2LMNACYP1A2PTGS1 | |
| SCHEMBL17049364 | 0.78 | C5AR1 (0.53) | FFAR1LTA4HKCNH2 | |
| SCHEMBL23483029 | 0.78 | LMNA (0.69) | FFAR1NR4A2LMNACYP1A2PTGS1 | |
| SCHEMBL1096817 | 0.78 | LMNA (0.69) | FFAR1NR4A2LMNACYP1A2PTGS1 | |
| SCHEMBL27367676 | 0.78 | LMNA (0.82) | NR4A2LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL339813 | 0.78 | LMNA (0.82) | NR4A2LMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104817553-B | The pyrimidinediamine class compound and its derivative and its medical usage of a kind of aromatic radical-heterocyclic substituted | 华东师范大学 | 2018-11-09 | — | — | CN | disclosed |
| EP-2403860-B1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE AS HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2403860-A2 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE AS HCV POLYMERASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010101967-A2 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | FFAR1 4662/4885NR4A2 2124/4885PPARG 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.